As of November 6, 2026, Relmada Therapeutics, Inc. is a publicly traded company (Nasdaq: RLMD); its largest reported holder is Janus Henderson, with 10.1% on Schedule 13G of February 6, 2026, then Squadron Capital Management LLC (9.9%). The largest insider holding is Sergio Traversa, the chief executive and a director, with 1,500,000 shares (1.4% of shares outstanding), per Form 4 of September 11, 2026 (Schedule 13G, February 6, 2026).
Is this your company?
About to sign with, pay or invest in Relmada Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Relmada Therapeutics, Inc. a real, registered company?
- Relmada Therapeutics, Inc. files with the SEC under CIK 1553643 (its SEC filings).
- Its shares are listed under the ticker RLMD on Nasdaq (SEC company record).
- Incorporated in Nevada; business address in Coral Gables, Florida, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under RELMADA THERAPEUTICS, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Squadron Master Fund LP (filed 2026-08-14).
Who are Relmada Therapeutics, Inc.'s owners and officers?
Relmada Therapeutics, Inc.: incorporated in Nevada; business address in Coral Gables, Florida; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Squadron Master Fund LP | 7% |
| Schedule 13G, 2026-07-29 | Blackrock, Inc. | 7% |
| Schedule 13G, 2026-06-22 | Millennium Management LLC | 4.4% |
| Schedule 13G, 2026-06-09 | Venrock Healthcare Capital Partners Iii, L.P. | 6.2% |
| Schedule 13G/A, 2026-05-13 | Adage Capital Management, L.P. | 4.54% |
| Schedule 13G, 2026-05-04 | Commodore Capital LP | 5.1% |
| Schedule 13G, 2026-02-17 | Spruce Street Capital LP | 5.57% |
| Schedule 13G/A, 2026-02-17 | Squadron Master Fund LP | 9.9% |
| Schedule 13G, 2026-02-12 | Adage Capital Management, L.P. | 5.82% |
| Schedule 13G, 2026-02-06 | Janus Henderson Group PLC | 10.1% |
| Schedule 13G, 2025-11-14 | Ikarian Capital, LLC | 4.8% |
| Schedule 13G/A, 2025-08-14 | Squadron Capital Management LLC | 9.9% |
Questions about who owns Relmada Therapeutics, Inc.
Who owns Relmada Therapeutics, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Relmada Therapeutics, Inc.: Janus Henderson Group PLC (10.1%, Schedule 13G, filed 2026-02-06), Squadron Capital Management LLC (9.9%, Schedule 13G/A, filed 2025-08-14), Squadron Master Fund LP (7%, Schedule 13G/A, filed 2026-08-14), Blackrock, Inc. (7%, Schedule 13G, filed 2026-07-29) and Venrock Healthcare Capital Partners Iii, L.P. (6.2%, Schedule 13G, filed 2026-06-09); 2 more are listed above.
Who are the largest shareholders of Relmada Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Relmada Therapeutics, Inc. on this page are Janus Henderson Group PLC (10.1%), Squadron Capital Management LLC (9.9%) and Squadron Master Fund LP (7%).
When did Janus Henderson Group PLC buy into Relmada Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group PLC on this page is the Schedule 13G, filed 2026-02-06, reporting 10.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Relmada Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Relmada Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Relmada Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Relmada Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 1,500,000 shares (1.4% of shares outstanding) (Form 4, 2026-09-11).
- , the chief financial officer: 1,000,000 shares (0.94% of shares outstanding) (Form 4, 2026-09-11).
- , the chief operating officer and a director: 502,295 shares (0.47% of shares outstanding) (Form 4, 2025-11-06).
- , the chief operating officer and cao: 403,931 shares (0.38% of shares outstanding) (Form 4, 2025-11-06).
Shares outstanding: 106,669,846 as of 2026-08-04, from the company's latest SEC cover page.
How much has Relmada Therapeutics, Inc. raised?
No fundraising or offering filing from Relmada Therapeutics, Inc. is on file with us.
Keep reading
More on Relmada Therapeutics, Inc. and the records around it.
Relmada Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Spruce Street Capital LP also filed stake reports on 1 other company: Research Alliance Corp III (Aug 2026)
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
- Ikarian Capital, LLC also filed stake reports on 22 other companies: Quoin Pharmaceuticals Ltd. (Oct 2026), Connect Biopharma Holdings Limited (Aug 2026), Galera Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/relmada-therapeutics